Immunocore Holdings (IMCR) EBIAT (2023 - 2025)
Immunocore Holdings (IMCR) has disclosed EBIAT for 3 consecutive years, with -$30.1 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 26.46% to -$30.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.5 million through Dec 2025, up 30.48% year-over-year, with the annual reading at -$35.5 million for FY2025, 30.48% up from the prior year.
- EBIAT hit -$30.1 million in Q4 2025 for Immunocore Holdings, down from -$177000.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $8.7 million in Q3 2024 to a low of -$30.1 million in Q4 2025.
- Historically, EBIAT has averaged -$11.8 million across 3 years, with a median of -$14.3 million in 2023.
- Biggest five-year swings in EBIAT: skyrocketed 864.24% in 2024 and later tumbled 102.03% in 2025.
- Year by year, EBIAT stood at -$19.7 million in 2023, then fell by 20.48% to -$23.8 million in 2024, then dropped by 26.46% to -$30.1 million in 2025.
- Business Quant data shows EBIAT for IMCR at -$30.1 million in Q4 2025, -$177000.0 in Q3 2025, and -$10.3 million in Q2 2025.